GlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical… Read more »
- Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer ImagingMELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces… Read more »
- Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a… Read more »
- Voting Rights and Shares Capital of the CompanyIn accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French… Read more »
- Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– Read more »
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics… Read more »
- Kyntra Bio to Participate in Upcoming Investor ConferencesSAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) — Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the… Read more »
- NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric CancerROCKVILLE, Md., Feb. 17, 2026 (GLOBE NEWSWIRE) — NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform… Read more »
- Genmab Announces Initiation of Share Buy-Back ProgramCompany Announcement Read more »
- Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial ReportFiling of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Read more »
- RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA +14.5%, ADJUSTED NET INCOME +14.5% Read more »
Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026
CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated… Read more »- Genmab Files Annual Report with the U.S. Securities and Exchange CommissionMedia ReleaseCOPENHAGEN, Denmark; February 17, 2026 Read more »
- Genmab Publishes 2025 Annual ReportCompany Announcement Read more »
- Adagene to Participate in Two Upcoming Investor ConferencesSAN DIEGO and SUZHOU, China, Feb. 17, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a… Read more »
- GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” SegmentAccess the “What This Means” segment here Read more »
- Psyence BioMed Announces Results of Annual and Special Meeting of ShareholdersNEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical… Read more »
- Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and ExtremitiesWOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing… Read more »
- Codexis to Participate in TD Cowen 46th Annual Health Care ConferenceREDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for… Read more »
- Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial OfficerSEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for… Read more »
- Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on averageFinal EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment. Read more »
- Lite Strategy Reports Fiscal 2026 Second Quarter ResultsLite Strategy Reports Fiscal 2026 Second Quarter ResultsDriven by Successful Deployment of Treasury Operations Read more »
- Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory BoardAppointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND… Read more »
- Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public OfferingCERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) — Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology… Read more »
- Moleculin Announces Notice of Allowance for Japanese Patent Covering AnnamycinHOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the… Read more »
- Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket TrialPARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) — Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying… Read more »
- ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND ClearanceSAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic… Read more »
- Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AAUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) — BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift:… Read more »
- Cellectar Biosciences Expands Global Intellectual Property EstateStrengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Read more »
- BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) — BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a… Read more »
- Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdateISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the… Read more »
- Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsWALTHAM, Mass. and BOULDER, Colo., Feb. 17, 2026 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on… Read more »
- Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic AtrophyBRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform… Read more »
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming… Read more »
- MediWound to Present at Upcoming Investor ConferencesMediWound to Present at Upcoming Investor Conferences Read more »
- Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory DiseasesIn two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Read more »
- Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026Management to host conference call on Thursday, February 26, 2026, at 8:00 am EST Management to host conference call on… Read more »
- Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical… Read more »
- Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseCAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on… Read more »
- Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceCMMB CEO Dr. Adi Mor will present at Oppenheimer’s virtual 36th Annual Life Sciences Healthcare Conference on Feb. 26 at… Read more »
- Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical… Read more »
- Sanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rdFORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI),… Read more »
- Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceTrevi Therapeutics’ senior management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Read more »
Cronos Launches New All-in-One Vape, Spinach PUFFERZ™
Spinach PUFFERZ™ delivers a flavorful experience combining high-quality cannabis with a sleek tactile design, enhanced with liquid diamonds Spinach PUFFERZ™… Read more »- GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth ConferenceSAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology… Read more »
- BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ETPALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical… Read more »
- Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic UpdateMainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update Read more »
- Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple SclerosisDuring year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50… Read more »
- Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human AlbuminDyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin Read more »
- Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound CleanserCompany expands ISO 13485/MDSAP Certification to support growing wound care portfolio Company expands ISO 13485/MDSAP Certification to support growing wound… Read more »